Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.
about
Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cellsInhibition of HIV-1 replication by a bis-thiadiazolbenzene-1,2-diamine that chelates zinc ions from retroviral nucleocapsid zinc fingersDrug-class specific impact of antivirals on the reproductive capacity of HIVThe y271 and i274 amino acids in reverse transcriptase of human immunodeficiency virus-1 are critical to protein stabilityMycobacterium tuberculosis complex enhances susceptibility of CD4 T cells to HIV through a TLR2-mediated pathwayHuman Ubc9 contributes to production of fully infectious human immunodeficiency virus type 1 virionsHigher-order oligomerization targets plasma membrane proteins and HIV gag to exosomes.Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection.Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activationA novel HIV-1-encoded microRNA enhances its viral replication by targeting the TATA box region.Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infantsA novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection.Inhibitory effect of aqueous Dandelion extract on HIV-1 replication and reverse transcriptase activityAnalyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.Short communication: antiretroviral therapy resistance mutations present in the HIV type 1 subtype C pol and env regions from therapy-naive patients in ZambiaMinocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells.HIV Pol inhibits HIV budding and mediates the severe budding defect of Gag-Pol.Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification.Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays.24 hours in the life of HIV-1 in a T cell lineA cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells.The HBV drug entecavir - effects on HIV-1 replication and resistanceNeutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.Identification of an inhibitory budding signal that blocks the release of HIV particles and exosome/microvesicle proteins.Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressorVariations in the Biological Functions of HIV-1 Clade C Envelope in a SHIV-Infected Rhesus Macaque during Disease Progression.Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses.Analysis of HIV-1 expression level and sense of transcription by high-throughput sequencing of the infected cellPhenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins.CD4+ T cells from elite suppressors are more susceptible to HIV-1 but produce fewer virions than cells from chronic progressors.Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.Antibody-free magnetic cell sorting of genetically modified primary human CD4+ T cells by one-step streptavidin affinity purificationDrug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea.ADP ribosylation factor 1 activity is required to recruit AP-1 to the major histocompatibility complex class I (MHC-I) cytoplasmic tail and disrupt MHC-I trafficking in HIV-1-infected primary T cells.Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.Medroxyprogesterone acetate increases HIV-1 infection of unstimulated peripheral blood mononuclear cells in vitro.Evolutionary and Functional Analysis of Old World Primate TRIM5 Reveals the Ancient Emergence of Primate Lentiviruses and Convergent Evolution Targeting a Conserved Capsid Interface
P2860
Q24548940-50F79923-3072-478D-930B-C998DD387678Q24605190-0739A29B-1178-47F9-98EA-5C203E9C3CA3Q28473451-9E0FD741-CE87-4719-BAFB-C2364375C51BQ28475710-12F77D74-9B3A-42BA-B3E0-6FBECE771A43Q28728928-B58EBB63-8AF6-479A-851B-A68249335931Q30436618-3593AC3F-A0B0-4741-8C62-A86C2B539415Q33286754-A36A81C4-8698-4BB6-B013-BE22FEC55FFAQ33382958-56564A65-4566-4DE1-B63B-F4A57284FC2FQ33508788-32865FE9-E727-4275-BBB2-C9D718E54E57Q33556837-F0A4000B-03A6-4175-AD7E-5BD38F918E47Q33561750-801B3225-6A3A-4B80-916B-943381C83A33Q33724247-BDE568D5-41B7-458B-837F-98ACA5DA661DQ34025414-51D9227C-5086-4E12-A0A9-3EEAE6815266Q34073041-5DE6F768-91A0-424E-BD6E-1FB86AF8AE58Q34087809-4A160432-F681-4E34-8EFE-408CA475199DQ34100228-24584879-9FA4-42F1-9E2A-7AE3BF2B1CDDQ34102337-6422DD76-5FEE-4802-90FE-A379651A3B87Q34123688-F3A227D3-184B-4619-8DEC-84103DCA9944Q34150117-A64882E7-54FD-4C72-BE1A-655D66D943F5Q34412763-6F275CF3-E5E9-4083-ADCE-FFF6173BB545Q34489422-7C26FECC-9F00-4CC3-B223-CA84A5435A6DQ34574897-CB7538A9-5150-4922-A36F-06F3071405A0Q34635742-3BA94C9E-1C4E-4083-9679-8C17EEA532D4Q34639926-E5D758B8-2759-412A-8860-EFC16B97C78AQ34647680-609D799A-D7DA-426A-9BCD-2B76533F0976Q34675246-443DEF13-6018-4FA4-A1C0-DCF5A45A06EEQ34780395-42F518ED-469A-499C-80A1-1F629826DF4AQ34806205-470DF755-8AB1-43E2-A928-1BBA3406B8AEQ34937254-EC2AA759-5C7A-4085-B02F-B95D5B9391A3Q35076929-6EFF840A-7F93-4592-8F11-67EB50FA7491Q35077515-C4CE4BDC-92D3-4C36-90C0-621F42AA8FBDQ35192915-3CF3EA7B-5745-47A1-B3B6-019EF58B8356Q35216907-360AB270-5B8C-475E-9280-55082B1724BBQ35237575-EDD1A3FC-E94A-4D2F-AD34-5015969E6179Q35382218-0F5A6F1D-D5C9-413B-A924-F6B29B2E33FEQ35497950-77389A13-1B90-4F96-A24E-D4956A007706Q35531422-C4F034D6-081A-44D1-A0EA-31E31A37ACDAQ35634404-D66763F5-449C-4C57-BEDC-AED3FAB09F93Q35676330-45A84D80-19F9-4950-A063-E484B7ACF17FQ35751229-213382B7-B0EB-40F3-A9B8-2B6DB1CA2EB4
P2860
Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Novel single-cell-level phenot ...... immunodeficiency virus type 1.
@en
type
label
Novel single-cell-level phenot ...... immunodeficiency virus type 1.
@en
prefLabel
Novel single-cell-level phenot ...... immunodeficiency virus type 1.
@en
P2093
P2860
P1433
P1476
Novel single-cell-level phenot ...... immunodeficiency virus type 1.
@en
P2093
Cecily Alcock
Daphne Monie
Deborah Persaud
Haili Zhang
Janet Siliciano
Joseph Cofrancesco
Tara Kiefer
P2860
P304
P356
10.1128/JVI.78.4.1718-1729.2004
P407
P577
2004-02-01T00:00:00Z